Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01224223 · ClinicalTrials.gov registry record
Myeloid Suppressors in Inflammation
A clinical trial, sponsored by University of South Florida.
- Completed
- Registry status
- 20
- Enrollment target
NCT01224223 is a clinical trial that has completed, run by University of South Florida. The registered enrollment target is 20 participants.
The verdict
NCT01224223 has completed, sponsored by University of South Florida.
- COMPLETED
- Registry status
- 20 participants
- Enrollment target
Study Summary
Myeloid-derived suppressor cells (MDSC) have been studied for their ability to suppress T cell responses in vivo and in vitro. As a result, MDSC can regulate cellular responses to chronic inflammatory conditions such as cancer, leading to the induction of tolerance and, ultimately, tumor escape from immune surveillance.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2010-10 |
| Est. Completion | 2012-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01224223
The ClinicalTrials.gov registry entry for NCT01224223 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of South Florida, which has 252 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01224223 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01224223 about?
NCT01224223 is a clinical study titled "Myeloid Suppressors in Inflammation". Myeloid-derived suppressor cells (MDSC) have been studied for their ability to suppress T cell responses in vivo and in vitro. As a result, MDSC can regulate cellular responses to chronic inflammatory conditions such as cancer, leading to the induction of tolerance and, ultimately, tumor escape from...
What is the current status of trial NCT01224223?
This trial is currently completed. The enrollment target is 20 participants. The study started on 2010-10. Estimated completion is 2012-01.
Who is sponsoring clinical trial NCT01224223?
This trial is sponsored by University of South Florida, which has 252 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.